Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
THE most anticipated pharma news of 2016 lived down to expectations. Following in the footsteps of nearly every other company that has sought to treat Alzheimer's disease, Eli Lilly announced last Wednesday that its Alzheimer's drug solanuzemab (sola) failed a huge Phase 3...